These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36544935)

  • 1. The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study.
    Sato R; Kumai T; Ishida Y; Yuasa R; Kubota A; Wakisaka R; Komatsuda H; Yamaki H; Wada T; Harabuchi Y
    Laryngoscope Investig Otolaryngol; 2022 Dec; 7(6):1808-1813. PubMed ID: 36544935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
    Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
    ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
    Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
    Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
    Nguyen V; Huq M
    J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
    Hashimoto K; Yasumatsu R; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
    Anticancer Res; 2022 Feb; 42(2):981-989. PubMed ID: 35093898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
    Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
    Front Immunol; 2022; 13():931429. PubMed ID: 36248782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
    Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
    Even C; Delord JP; Price KA; Nakagawa K; Oh DY; Burge M; Chung HC; Doi T; Fakih M; Takahashi S; Yao L; Jin F; Norwood K; Hansen AR
    Eur J Cancer; 2022 Aug; 171():259-268. PubMed ID: 35777186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
    Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
    In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.